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Abstract The rise in multidrug resistant (MDR) bacteria
has become a global crisis. Rapid and accurate diagnosis of
infection will facilitate antibiotic stewardship and preserve
our ability to treat and cure patients from bacterial infection.
Direct in situ imaging of bacteria offers the prospect of
accurately diagnosing disease and monitoring patient out-
comes and response to treatment in real-time. There have
been many recent advances in the field of optical imaging of
infection; namely in specific probe and fluorophore design.
This combined with the advances in imaging device tech-
nology render direct optical imaging of infection a feasible
approach for accurate diagnosis in the clinic. Despite this,
there are currently no licensed molecular probes for clinical
optical imaging of infection. Here we report some of the
most promising and interesting probes and approaches under
development for this purpose, which have been evaluated in
in vivo models within the laboratory setting.
Keywords Optical  Fluorescence  Infection  Bacteria 
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Introduction
Multidrug resistant (MDR) bacteria are now responsible for
upwards of 23,000 deaths per year in the USA and 25,000
deaths per year within the EU; leading to total economic
burdens of $35 bn and €1.5 bn, respectively [1, 2]. The
inexorable rise of MDR bacteria has in large part been
exacerbated by misdiagnosis and inappropriate use of
antibiotics [3–6]. Accelerated development of diagnostic
approaches is imperative in order to gain control and
optimise infection treatment [7]. Improved antimicrobial
stewardship will be essential to safeguard not only treat-
ment of bacterial infections, but also to preserve many
procedures common to modern medicine where an inability
to prevent infection would deem them too risky to perform
[8]. These include cancer chemotherapy, dialysis for end
stage renal failure, organ and bone marrow transplantation
and complex surgery, such as cardiac bypass [1]. On this
basis, there is increasing pressure to find methods for the
accurate and rapid diagnosis of infection; and in situ
molecular imaging presents an ever-attractive tool to
achieve this.
Molecular imaging
Molecular imaging is an approach which, broadly speak-
ing, utilises a functional group to target disease biomarkers
or pathways conjugated to an imaging contrast agent, such
as a radionuclide or fluorophore. Due to the specificity of
these tracers, this approach has the potential to provide a
dynamic assessment of a disease site, enabling host–
pathogen interactions to be elucidated and the microenvi-
ronment to be monitored (e.g. the presence of specific
enzymes or pH of the surrounding tissue) rapidly and in
real-time. An approach which is much more difficult to
achieve using conventional molecular laboratory tests
performed ex vivo.
Imaging and sensing infection within the context of the
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1. Is the clinical presentation caused by bacteria or sterile
inflammation?
2. Are the bacteria Gram positive or Gram negative?
3. Are the bacteria pathogenic; are they MDR?
4. Is the innate host response sufficient to kill and remove
the pathogens or should we treat with antimicrobials or
other immunomodulatory approaches?
5. Has treatment been effective; should treatment be
continued or de-escalated?
To date, direct in situ real-time detection of infection
has largely relied upon nuclear imaging of suspected
infection with [18F]FDG (2-fluoro-2-deoxy-D-glucose) or
radiolabelled leukocytes. Despite the high sensitivity of
[18F]FDG, it has low specificity for bacterial infection and
may result in misdiagnosis [9–15]. Conversely, leukocytes
radiolabelled with Indium-111, Technicium-99m or
[18F]FDG should provide enhanced specificity for bacterial
infection compared to [18F]FDG [16–19], however, in
practice specificity has shown to be varied [20, 21]. Other
limitations of radiolabelled leukocyte imaging include the
lengthy procedure required for retrieving and labelling
leukocytes. Additionally, recovering enough leukocytes
from immunocompromised patients for the procedure is
not always possible, and not all bacterial infections elicit a
robust neutrophil response, such as Mycobacterium
tuberculosis.
Each of these existing ‘gold standard’ imaging tech-
niques rely on imaging surrogates of the response to
infection rather than targeting bacteria directly. Hence
these methodologies are inherently lacking in ability to
determine bacterial load or Gram status. Therefore, there is
a concerted effort to develop bacteria specific radionuclide
probes [22–33]. These probes are ultimately designed with
a target product profile to have high sensitivity and speci-
ficity; meaning infection loci can be accurately identified
by whole body imaging. These probes also strive to
quantify bacterial load, elucidate the Gram status of the
bacterial infection and be used to monitor treatment pro-
gression. However, there are several fundamental limita-
tions associated with nuclear medicine, which are unlikely
to be overcome with new generation bacterial tracers.
Namely this is the cost associated with the labelling and
synthesis of these probes; their short shelf-life due to decay
of the radionuclide; the radiation dose to the patient and
medical staff; and that the whole body scanning procedure
is not suitable for some patients, e.g. for those in intensive
care or in theatres; where near-patient imaging is optimal
(some hand held devices are now available, however, the
use of radioactivity in complex clinical environments is
challenging and not always possible). Therefore, the
development of optical molecular imaging tools based on
fluorescence reporters is gaining in popularity, especially
for superficial surfaces of the human body; such as skin or
those accessible by endoscopy. Whilst these probes are
designed to stand alone, it is highly likely that these probes
would be used in combination with current whole body
imaging; for example [18F]FDG could be used to determine
potential infectious loci, which could then be further
investigated and monitored with optical probes. This
approach may be clinically important for patients with
fever of unknown origin (FUO).
Optical molecular imaging
Optical molecular imaging relies on the detection of fluo-
rescence at a target site. Despite its widespread use within
the laboratory for generating insight into biological pro-
cesses in small animal models, optical imaging for human
diagnostics has not yet widely gained adoption within the
clinical setting. This has been for a number of reasons;
including poor signal to noise of fluorophores within the
body, the lack of specificity and sensitivity of available
probes, toxicity, and the inherent issue of light scattering
and absorbance within tissues. The current challenges are
discussed in further detail by Keereweer [34], thus to date,
no optical probes have been licensed for use or extensively
evaluated within the clinic for bacterial detection. Despite
this, optical imaging has shown its feasibility in the field of
oncology where its worth has been demonstrated using
intraoperative imaging devices for image guided surgery
[35].
Moreover, due to recent advances in both fluorophore
design and synthesis, and in imaging technology [36],
many of the limiting factors associated with optical
imaging can now be addressed and minimised, and on-
going efforts towards infection detection in vivo are pro-
ducing a variety of interesting probe candidates.
There is an ever-increasing number of available fluo-
rophores with desirable characteristics for in vivo and
clinical imaging. These fluorophores are shifted towards
the near infrared (NIR, 700–900 nm) region of the elec-
tromagnetic spectrum [37–39] and therefore have reduced
tissue absorbance and scattering, so that they can be
detected from greater depths and allow for more sensitive
imaging [40–42]. Furthermore, indocyanine green (ICG)
which fluoresces in the NIR region has US Food and Drug
Administration (FDA) clinical approval and has been
evaluated extensively in humans [43].
Whilst shifting excitation and emission spectra towards
the NIR region is imperative for enabling sensitive imaging
of below the skin surface [42], other considerations for
fluorophore development must be considered in order to
make them useful. For example: the aqueous solubility,
photostability, lack of auto quenching, ease of conjugation
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to targeting moieties, effect on the targeting moiety,
function, biodistribution, and clearance route to name but a
few. As shown by examples later within this review, there
are several NIR fluorophores which make interesting can-
didates for optical imaging of bacterial infections in vivo.
The emergence of environmentally sensitive fluorophores
and exploitation of FRET (fluorescence resonance energy
transfer) systems has also been conducive to the progression
of optical imaging probe design. NBD (7-nitrobenz-2-oxa-
1,3-diazol-4-y) is one such environmentally sensitive fluo-
rophore [44]; within an aqueous environment, NBD fluo-
resces weakly, whereas strong fluorescent signal can be
detected from hydrophobic regions, such as the cell mem-
brane. It must be noted that due to the short emission
wavelength of NBD (kem max = 535 nm), NBD is not a
fluorophore suited at all applications due to high tissue
autofluorescence at this wavelength, however as discussed
later, NBD has been exploited for some applications and can
be detected above tissue background using fibred confocal
fluorescence microscopy (FCFM) [45]. FRET systems
exploit the phenomenon of fluorescence quenching. If a
fluorophore is placed in close proximity to a quencher, the
quencher is able to accept the energy emitted from the
excited fluorophore, preventing fluorescence signal emission
from the probe. In the context of optical imaging probes, the
fluorophore and quencher are often located either side of a
specific peptide sequence. Cleavage of the peptide sequence
by a target enzyme releases the quencher from the molecule,
thus enabling fluorescent signal to be detected. This
approach has been exploited to target several bacteria
specific enzymes, such as b-lactamase [46] and micrococcal
nuclease [47], as discussed later.
Additionally, the advancement in hand held-devices and
optical endomicroscopy (OEM) platforms such as fibred
confocal fluorescent microscopes (FCFM) mean that
imaging of shallow infections and those in internally
accessible areas such as lungs, stomach, gut etc. can be
performed at the bedside without the need to move patients
to cumbersome equipment, as is required for nuclear
imaging and magnetic resonance imaging (MRI).
Due to the lack of reported clinical data for the evaluation
of optical bacteria-specific molecular imaging probes, this
review will report and comment on some of the most
promising optical imaging agents under development, which
have thus far been evaluated in vivo in small animal models.
Current probes undergoing in vivo assessment
in small animal models
Probes for optical imaging are dependent on two key fac-
tors; the targeting region and the fluorophore (and quencher
if applicable). Both of which are crucial for specific,
sensitive imaging tools. Whilst this review is primarily
focused on optical imaging of bacterial infections in vivo,
probe development for the field of molecular imaging has
largely been geared towards nuclear imaging. For this
reason, where appropriate, examples from nuclear medi-
cine are reported in the context of optical probe design.
Table 1 lists optical probes currently under development as
discussed within this review, including their key features
and models of pre-clinical evaluation.
As is evidenced from Table 1 and the forthcoming dis-
cussion of reported molecular probe data, it is challenging
to directly compare probe performance. This is due to
the variation in study design; including the pathogen cho-
sen, inoculation dose and infection site; the host immune
status; the choice of controls; the injected probe route,
concentration and determination of when peak signal to
noise is likely to be achieved. It must be noted that the
variance in study design is not limited to pre-clinical
optical imaging, but is also common place in the field of
pre-clinical nuclear imaging. Whilst extrapolating infor-
mation from individual studies in order to compare probes
across the field is difficult, the optical probes discussed in
the remainder of this review each demonstrate potential for
translation to the clinical setting.
Antimicrobial peptides
Antimicrobial peptides (AMPs) form part of the innate
immune response. They are small amphipathic molecules
and are able to readily insert into negatively charged bac-
terial membranes, thus offering a potential means for
bacteria specific detection.
Ubiquicidin (UBI) is an AMP which shows much pro-
mise for diagnosing infection within the field of nuclear
medicine. A number of studies pre-clinically [23–25, 28]
and clinically [27] have demonstrated that a Technetium-
99m radiolabelled UBI fragment, [99mTc]-UBI29–41 was
able to specifically target a number of infection types,
proving accurate diagnosis for at least 95 % of human
patients for diseases including diabetic foot [48], fever of
unknown origin [49], osteomyelitis [50] and hip prosthesis
[51]. [99mTc]-UBI29–41 imaging has also shown promise in
monitoring responses to treatment in vivo [23, 26] and
clinically [52].
The same UBI29–41 fragment was subsequently labelled
with NIR dye ICG02 and evaluated in vivo against Gram
positive and Gram negative infections. This ligand was
shown in vivo to have deep tissue penetration, and fast
clearance. Moreover, the probe was able to accumulate at
sites of bacterial infection and not at sites of sterile
inflammation. Free dye did not accumulate at the infection
site, and the probe could be blocked by pre-injections of
unlabelled UBI29–41 [53].
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An alternative approach for utilising the UBI29–41 frag-
ment for bacterial imaging saw modification of the peptide
structure in a number of ways, resulting in a cyclic form
[45]. This led to improved peptide stability and resistance
to proteolytic degradation, which had been observed for
linear derivations of fluorescently labelled UBI29–41. In
addition, the modified UBI scaffold was conjugated to the
environmental fluorophore NBD (7-nitrobenz-2-oxa-1,3-
diazol-4-y), enabling the probe to switch from ‘off’ to ‘on’
when inserted within a bacterial membrane. Despite NBD
emitting in the ‘green’ region of the electromagnetic
spectrum, using fibred confocal fluorescence microscopy
(FCFM) the researchers were able to demonstrate that
bacteria were labelled and visible above the level of tissue
autofluorescence within ex vivo human lung tissue.
Further to labelling the linear UBI29–41 fragment with a
radiolabel or a fluorophore, other approaches have been
taken in order to multiplex fluorescently labelled UBI29–41
with either an antimicrobial for treatment of infection [54],
or with a radiolabel for dual nuclear–optical imaging of
infection [55].
To demonstrate the theranostic potential of fluorescently
labelled UBI29–41 in vivo, UBI29–41 was conjugated to
ZnO-quantum dots and NIR fluorophore MPA (a hydro-
philic derivative of ICG) to yield ZnO@BSA-PEP-MPA
for diagnosis of both Gram positive and Gram negative
infections [54]. ZnO@BSA-PEP-MPA was further modi-
fied to incorporate the Gram positive antimicrobial van-
comycin (Van). Whilst in vivo imaging of
Van@ZnO@BSA-PEP-MPA does not appear to have been
performed, the group showed in their murine model that
the Van@ZnO@BSA-PEP-MPA probe was more effective
at killing Staphylococcus aureus compared to free van-
comycin alone; demonstrating that their approach was
successful for combining non-invasive bacterial infection
diagnosis and targeted treatment.
Development of a dual optical–nuclear probe for
imaging infection circumvents the potential limitation of
relying on optical imaging alone for identifying infectious
foci by enabling non-invasive whole body imaging by PET
or SPECT. This should identify infection sites indepen-
dently of tissue depth and autofluorescence, which may be
prohibitive for whole body optical imaging. After identi-
fication of suspected infection sites, the optical element of
the probe can be imaged and monitored during interven-
tion, such as surgical resection or treatment. The effec-
tiveness of this approach has previously been demonstrated
clinically for sentinel node biopsy [56, 57].
The potential of dual modality imaging of infection with
UBI29–41 has been demonstrated in murine models of S. aur-
eus (Gram positive) and Klebsiella pneumoniae (Gram neg-
ative) intramuscular infections, where UBI29–41 was dual-
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Cy5-UBI29–41 [55]. This probe accumulated at the sites of
bacterial infection after intravenous (i.v) injection and could
be detected by sequential SPECT and optical imaging.
Zn-DPA
Zn-DPA (zinc-(II)-dipicolyamine) is positively charged
metal complex, and as such, it readily interacts with neg-
atively charged membranes of both Gram positive and
Gram negative bacterial cells, but not with the membranes
of healthy mammalian cells [58, 59].
A number of differently labelled versions of Zn-DPA
have been developed and evaluated in vivo with S. aureus
infection models; including a Cy5-like-labelled ZnDPA
probe [60] and a NIR-cyanine-labelled Zn-DPA [61, 62],
the latter of which is now commercially available (Li-Cor
Biosciences). Furthermore, Zn-DPA conjugated to squar-
aine-rotaxane moieties have also been developed in order
to increase brightness and circumvent some of the known
limitations of carbocyanine (Cy) dyes such as poor pho-
tostability [59, 63, 64].
Despite the successful in vivo labelling of bacterial
infections in several studies [59–64], it must be noted that a
fundamental flaw of Zn-DPA imaging is that Zn-DPA also
labels negatively charged membranes of apoptotic and
necrotic mammalian cells [65, 66]. This leads to false
identification of bacterial infection by labelling sites of
sterile inflammation, and thus renders it a non-specific
imaging agent [60–62, 64].
Sugars
Bacteria and mammalian cells utilise different sugars,
hence targeting bacteria specific sugar transport systems is
a promising approach for probe design. To date, probes
targeting maltohexaose, glucose-6-phosphate and sorbitol
transport systems have been reported.
Maltohexaose is a sugar utilised by many bacteria [67],
it is transported into bacteria via the maltodextrin trans-
porter which is absent from mammalian cells [68, 69].
When labelled with the NIR dye IR786, the maltodextrin-
based imaging probe (MDP) was shown to accumulate at
sites of Escherichia coli infections in vivo and within S.
aureus biofilms in vitro specifically due to uptake by the
maltodextrin transport pathway. Due to the high activity of
the bacterial maltodextrin transporter and the hydrophilic
nature of MDP (meaning it cannot diffuse through mam-
malian cell membranes [70]), the probe demonstrated high
signal to noise and showed high sensitivity compared to
other bacterial targeting agents, including ZnDPA [71].
However, as with all metabolite-based probes, accumula-
tion of the probe is likely to be dependent on the metabolic
state of the bacteria.
Glucose-6-phosphate (G6P) is a sugar utilised only by
certain bacteria; including E. coli and S. aureus [72]. It is
transported into bacteria via a Universal Hexose Phosphate
Transporter (UHPT) which is not expressed at the cell
surface of mammalian cells. Therefore, UHPT is an ideal
candidate for delivery of targeted bacteria specific probes.
The feasibility of targeting UHPT for infection detection
has been demonstrated with the G6P analogue [18F]FDG-6-
P by nuclear imaging techniques [73]. Converting glucose
to glucose-6-phosphate is achieved through a very simple
hexokinase reaction; therefore, it could be possible to
convert fluorescently labelled glucose to fluorescently
labelled glucose-6-phosphate. Both environmentally sen-
sitive NBD [74, 75] and NIR [76] glucose derivatives have
been reported. Whilst NBD-glucose has been shown to be
transported by specifically glucose transporters, the NIR
labelled equivalent was not, speculatively due to the larger
size of the NIR fluorophore [77]. However, it is not known
whether the phosphorylated versions of these probes would
be recognised by the UHPT.
Sorbitol is a metabolite utilised by the Gram negative
Enterobacteriaceae family of bacteria [78]. These bacteria
include E. coli, K. pneumoniae and Pseudomonas aerugi-
nosa and are the main cause of Gram negative bacterial
infections in humans. In order to target these bacteria
in vivo, [18F]FDG was modified to produce 2-[18F]-fluo-
rodeoxysorbitol ([18F]FDS). The probe was able to
specifically differentiate sites of Enterobacteriaceae infec-
tion from Gram positive infection and sites of sterile
inflammation in a range of infection sites; including brain
and lung. Additionally, this probe was able to monitor
infection levels during treatment of antibiotic sensitive and
resistant E. coli infections [79]. The biodistribution and
stability of [18F]FDS has since been evaluated clinically in
a healthy volunteer, and was shown to be consistent with
that of murine models [80]. Despite this promising route
for targeting Enterobacteriaceae, fluorescently labelled
sorbitol derivatives for optical imaging are yet to be
reported.
Concanavalin A nanoprobe
Concanavalin A (Con A) is a lectin-binding protein with a
high affinity for cell-surface mannose residues and other
polysaccharides within the cell wall of Gram positive and
Gram negative bacteria. To exploit Con A as a bacterial
imaging tool, Con A was conjugated to a nanoparticle
carrier and near NIR dye IR750 [81]. The Con A-IR750
nanoprobe was demonstrated to adhere to sites of superfi-
cial S. aureus wound site infections, and at sites of infected
transcutaneously implanted catheters in mice. For each of
these infection models the nanoprobe was added topically
followed by a wash step and imaging. Fluorescence signal
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from the wound site was detected and increased propor-
tionally with bacterial load.
Nuclease-activated FRET probe
Nucleases are a diverse group of enzymes responsible for
the degradation of nucleic acids (through specific cleavage
of the phosphodiester bonds between nucleotide subunits).
Several modified oligonucleotides have been identified
which show resistance to degradation by mammalian
nucleases, but are susceptible to cleavage by certain bac-
terial nucleases [82]. One of the identified oligonucleotides
was sensitive to digestion specifically by S. aureus
Micrococcal Nuclease (MN), but resistant to mammalian
serum nucleases [47].
This identified oligonucleotide was further modified to
incorporate a FRET (fluorescence resonance energy trans-
fer) system, where a Cy5.5 fluorescence group was incor-
porated 50 of the enzyme cleavage site, and quenching
groups (ZEN and Iowa Black RQ) 30 of the cleavage site.
The probe was silent until contact and cleavage by MN,
enabling identification of S. aureus infections in vivo
within 15 min of i.v administration.
b-Lactamase-activated FRET probe
b-Lactamase is an enzyme produced by many bacteria
and confers resistance to b-lactam antibiotics, such as
penicillin [83–86]. The structure of b-lactamase encoded
by Mycobacterium tuberculosis (M. tb) differs to that
produced by other bacterial species and is known to be
highly active [87, 88]. It has therefore has been exploi-
ted for detection of M. tb using a FRET-based NIR
(Cy5.5 and QSY21/QSY22) substrate for M. tb b-lacta-
mase. A number of probes were evaluated in subcuta-
neous in vivo murine models of M. tb infections [46],
with each candidate accumulating and being activated at
the site of infection. The probe with the highest sensi-
tivity was selected for further investigation of pulmonary
M. tb infection. Following i.v administration the probe
was able to reach the site of infection, was activated and
was detectible in situ with a high signal to noise. Signal
was not detected in the lungs of non-infected mice both
in situ and ex vivo.
Prothrombin
A mechanism of S. aureus immune evasion is to clot
human blood through the binding of staphylocoagulase to
prothrombin [89–91]. This phenomenon has been exploited
to enable S. aureus detection in vivo in mouse models of
endocarditis by optical imaging of an Alexa Fluor 680
labelled prothrombin analogue, AF680-Pro-T [92].
Accumulation of the probe at the infection site was shown
to be specific to coagulase positive S. aureus; with no probe
detected at sites of coagulase negative Staphylococcus
epidermidis infection or non-infected controls.
Nitroreductase-activated probe
Nitroreductases are widespread throughout both Gram
positive and Gram negative bacterial species, and therefore
their exploitation through optical imaging would act as a
general bacterial infection identifier [93]. This has been
demonstrated by using the self-quenched NIR fluorophore
CytoCy5S, which is reduced by nitroreductase to yield
fluorescence signal [94]. Through this approach it was
possible to detect a number of pathogens in different
murine infection models in vivo by whole body imaging,
including intramuscular E. coli infections, liver and spleen
Salmonella typhimurium infections, and tumour colonisa-
tion by E. coli and Bifidobacterium breve.
Antibiotics
Historically, there have been numerous attempts at devel-
oping antibiotics as bacterial imaging agents [95]. The
most widely explored was the commercially available
probe Infecton ([99mTc]-ciprofloxacin) [96, 97]. Radiola-
belled ciprofloxacin was anticipated to act as a general
identifier of Gram positive and Gram negative bacterial
infection; however, in vivo investigations and patient
clinical studies demonstrated varying degrees of success;
indicating that it may not enable a clear distinction between
bacterial infection and sterile inflammation [98–101]. Due
to the inconclusive data, development of infection was
ceased in 2007.
More recently, a NIR-labelled vancomycin probe has
begun in vivo evaluation. Vancomycin binds directly to the
cell wall of Gram positive bacteria [102], and therefore
accumulates at sites of infection. When Vancomycin-
IRDye800CW was injected i.v into mice harbouring
bilateral S. aureus and E. coli infections, the probe could be
detected selectively in the S. aureus infected flank [103].
Moreover, this group also studied the feasibility of using
Vancomycin-IRDye800CW to detect Gram positive bio-
films on implanted medical devices within human cadav-
ers. Osteosynthetic devices were coated with S. epidemidis
biofilms pre-labelled with Vancomycin-IRDye800CW, and
implanted into lower leg of cadavers. Fluorescence signal
was detected through the skin using an intraoperative
clinical multispectral imaging camera, whereas no signal
was detected for bacteria free controls. It has not yet been
determined whether this approach would be suitable for
imaging deeper infections within the body, such as hip
prosthesis or endocarditis.
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A major drawback of targeting bacteria with radiola-
belled antibiotics is that bacteria which are already resistant
to the drug are unlikely to accumulate the probe, and as
such could result in false negative results. Moreover, there
are questions surrounding what effect administering sub-
lethal doses of antibiotic probe may have on promoting
antimicrobial resistance [104]; however, the dose required
for imaging will remain low and this is likely to not be an
issue.
Bacteriophage
The bacteriophage M13 (a filamentous, non-lytic phage with
natural affinity for the E. coli F’ pili [105, 106]) has been
exploited for bacterial targeting in vivo. Bacteriophage M13
was used as a scaffold for attaching single-walled carbon
nanotubules (SWNTs). These fluoresce in the NIR-II region
of the electromagnetic spectrum (900–1400 nm) [107],
resulting in reduced tissue scattering and enhanced depth
penetration, providing a potential improved signal to noise
by 100-fold compared to other NIR probes (700–900 nm)
[108–111]. The M13-SWNT probe was able to discriminate
between F0 positive and F0 negative E. coli soft tissue
infections in a mouse model with a custom made NIR-II
imaging device. The M13-SWNT probe was further modi-
fied to contain an anti-S. aureus antibody (anti-S. aureus-
M13-SWNT), which enabled specific targeting to soft tissue
and endocarditis S. aureus infections in mice, and demon-
strated the potential of bacteriophage-mediated imaging of
infections other than E. coli.
Future perspectives
As the global number of MDR pathogens continues to rise,
the urgency to answer the question of whether to treat or
not, whether treatment is effective, and when to stop
treatment on a case-by-case basis is imperative. To this
end, a range of bacterial probe targets have been identified
and the approaches under development to image these are
varied. Whilst the emphasis in recent years has been to
develop tools for specifically imaging infection by nuclear
medicine, the cost, short shelf-life and radiation dose
exposure are all undesirable characteristics inherent to this
approach. The expanding field of optical probe design
presents an alternative means to detect infections in situ
whilst circumventing many of the drawbacks of nuclear
imaging. Whilst optical imaging approaches do have sev-
eral potential limitations; such as low sensitivity, poor
depth penetration and unavoidable tissue autofluorescence;
advances in detection technology and the availability of
self-quenched, FRET-systems, environmentally activated,
and ‘always-on’ fluorophores with distinct spectral
properties could minimise these limitations and offer
advantages for multiplexing probes and improve signal to
noise compared to ‘always-on’ radionuclides.
It is clear that infection specific molecular probes for
both nuclear and optical imaging modalities should con-
tinue to be developed in order to solve the unmet clinical
need for rapid and accurate in situ diagnostics of a range of
bacterial species. It is unlikely that whole-body optical
imaging will ever be feasible to identify unknown infection
loci sites. For this type of investigation, radiolabelled
probes offer a clear advantage. Despite this, optical probes
my offer advantages during surgical intervention, identi-
fying prosthetic joint infections or in locations accessible
by optical endoscopes, such as for pulmonary infection.
There are currently no molecular probes licensed for
clinical optical imaging of infection. However, the field of
optical imaging of infection is rapidly expanding and is
poised for evaluation of lead probes in first-in-man clinical
studies within the coming years; where on-target labelling,
ability to target MDR bacteria, ability to target bacteria
within a biofilm, probe sensitivity limits and probe
biodistribution will be evaluated. We predict that the
likeliest probes to be accelerated into clinical practice will
be fluorescently labelled antibiotic derivatives and modi-
fied antimicrobial peptides. The versatility of optical
molecular imaging of bacterial infections is immense and
the potential to multiplex to image host–pathogen inter-
actions will lead to a new generation of biological insights.
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